Literature DB >> 17603762

Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.

M Saraste1, H Irjala, L Airas.   

Abstract

We studied how interferon-beta (IFN-beta) treatment of relapsing-remitting multiple sclerosis (MS) affects subgroups of natural killer cells (NK cells). Following IFN-beta treatment, there was an expansion of CD56(Bright) NK-cells in the peripheral blood of MS patients, while at the same time the proportion of CD56(Dim) cells was diminished. In a control group, the proportion of CD56(Bright) NK-cells was significantly higher in secondary lymphoid tissues compared to the peripheral blood of the same individual. Our findings confirm that CD56(Bright) NK-cells preferably locate within the secondary lymphoid tissues, where they may interact with T cells and thereby contribute to the control of the disease activity in MS.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17603762     DOI： 10.1007/s10072-007-0803-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  26 in total

1.  Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity.

Authors:  R B Smeltz; N A Wolf; R H Swanborg
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

2.  Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire.

Authors:  J J Campbell; S Qin; D Unutmaz; D Soler; K E Murphy; M R Hodge; L Wu; E C Butcher
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  NK cell-mediated lysis of autologous human oligodendrocytes.

Authors:  R H Morse; R Séguin; E L McCrea; J P Antel
Journal:  J Neuroimmunol       Date:  2001-05-01       Impact factor: 3.478

4.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

Authors:  Todd A Fehniger; Megan A Cooper; Gerard J Nuovo; Marina Cella; Fabio Facchetti; Marco Colonna; Michael A Caligiuri
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

5.  IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells.

Authors:  F D Shi; K Takeda; S Akira; N Sarvetnick; H G Ljunggren
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

6.  Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

Authors:  M A Cooper; T A Fehniger; S C Turner; K S Chen; B A Ghaheri; T Ghayur; W E Carson; M A Caligiuri
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

7.  The regulatory role of natural killer cells in multiple sclerosis.

Authors:  Kazuya Takahashi; Toshimasa Aranami; Masumi Endoh; Sachiko Miyake; Takashi Yamamura
Journal:  Brain       Date:  2004-06-30       Impact factor: 13.501

8.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

Review 9.  Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

Authors:  V Wee Yong
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

10.  Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells.

Authors:  B Zhang; T Yamamura; T Kondo; M Fujiwara; T Tabira
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307
View more
  57 in total

Review 1.  Adaptive immune responses mediated by natural killer cells.

Authors:  Silke Paust; Balimkiz Senman; Ulrich H von Andrian
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 3.  The role of natural killer cells in curbing neuroinflammation.

Authors:  Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2007-09-29       Impact factor: 3.478

Review 4.  CD56bright natural killer (NK) cells: an important NK cell subset.

Authors:  Aurélie Poli; Tatiana Michel; Maud Thérésine; Emmanuel Andrès; François Hentges; Jacques Zimmer
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

5.  Low-dose IL-2 induces CD56bright NK regulation of T cells via NKp44 and NKp46.

Authors:  S T Loughran; P A Power; S L McQuaid; P Maguire; A Szczygiel; P A Johnson
Journal:  Clin Exp Immunol       Date:  2020-02-13       Impact factor: 4.330

6.  Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.

Authors:  Eduardo Huarte; Agnieszka Rynda-Apple; Carol Riccardi; Jerod A Skyberg; Sarah Golden; Maryclare F Rollins; Andrew G Ramstead; Larissa O Jackiw; Massimo Maddaloni; David W Pascual
Journal:  J Autoimmun       Date:  2011-10-22       Impact factor: 7.094

7.  Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells.

Authors:  Philip L De Jager; Elizabeth Rossin; Saumyadipta Pyne; Pablo Tamayo; Linda Ottoboni; Vissia Viglietta; Mira Weiner; Dulce Soler; Elena Izmailova; Lauren Faron-Yowe; Carmeline O'Brien; Sam Freeman; Susana Granados; Alex Parker; Ronenn Roubenoff; Jill P Mesirov; Samia J Khoury; David A Hafler; Howard L Weiner
Journal:  Brain       Date:  2008-06-21       Impact factor: 13.501

8.  Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus.

Authors:  Danika Schepis; Iva Gunnarsson; Maija-Leena Eloranta; Jon Lampa; Stefan H Jacobson; Klas Kärre; Louise Berg
Journal:  Immunology       Date:  2008-06-18       Impact factor: 7.397

9.  Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells.

Authors:  Sonemany Salinthone; Robynn V Schillace; Gail H Marracci; Dennis N Bourdette; Daniel W Carr
Journal:  J Neuroimmunol       Date:  2008-06-17       Impact factor: 3.478

Review 10.  Regulatory NK-cell functions in inflammation and autoimmunity.

Authors:  Anna Lünemann; Jan D Lünemann; Christian Münz
Journal:  Mol Med       Date:  2009-05-11       Impact factor: 6.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.